Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: TechSci Research | PRODUCT CODE: 1881741

Cover Image

PUBLISHER: TechSci Research | PRODUCT CODE: 1881741

Albumin Excipient Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By End user, By Region and Competition, 2020-2030F

PUBLISHED:
PAGES: 187 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 4500
PDF and Excel (Multi-User License)
USD 5500
PDF and Excel (Custom Research License)
USD 8000

Add to Cart

We offer 8 hour analyst time for an additional research. Please contact us for the details.

The Global Albumin Excipient Market, valued at USD 4.98 Billion in 2024, is projected to experience a CAGR of 8.01% to reach USD 7.91 Billion by 2030. Albumin excipient is a highly purified protein, typically derived from human plasma or engineered recombinantly, utilized in pharmaceutical formulations as an inactive ingredient. Its primary functions include stabilizing active drug components, enhancing solubility, prolonging product shelf-life, and serving as a crucial element in cell culture media, vaccine production, and advanced drug delivery systems. The market's expansion is significantly driven by the escalating global demand for biopharmaceuticals and biologics, an increasing incidence of chronic diseases necessitating intravenous therapies, and continuous technological advancements in albumin production and purification processes.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 4.98 Billion
Market Size 2030USD 7.91 Billion
CAGR 2025-20308.01%
Fastest Growing SegmentHuman Serum Albumin
Largest MarketNorth America

Key Market Drivers

The global albumin excipient market is significantly propelled by the increasing demand for biopharmaceuticals and biologics, which rely heavily on albumin for stabilization and enhanced delivery. As the pharmaceutical industry increasingly focuses on complex protein-based therapies, albumin's unique properties as a non-immunogenic and effective stabilizer become indispensable. For example, according to the FDA's Center for Drug Evaluation and Research (CDER), in 2024, biologics accounted for 32% of all new drug approvals, a notable increase from the 28% average over the prior six years. This expanding pipeline and approval rate directly translate into a greater need for high-quality albumin excipients to ensure the safety, efficacy, and shelf-life of these advanced therapeutic products.

Key Market Challenges

The challenging factor for the Global Albumin Excipient Market is the inherently high production costs associated with both plasma-derived and recombinant albumin manufacturing. This significant impediment stems from the complex and resource-intensive processes required for both sources. For plasma-derived albumin, extensive collection networks, rigorous purification, and stringent safety testing contribute substantially to expenses. Similarly, recombinant albumin manufacturing necessitates sophisticated biotechnological processes, specialized equipment, and considerable research and development investments. These factors collectively drive up the cost of the final excipient.

Key Market Trends

The increasing adoption of recombinant albumin excipients addresses critical supply and safety considerations. Unlike plasma-derived albumin, recombinant alternatives offer enhanced consistency, a reduced risk of viral contamination, and overcome the ethical and supply chain challenges associated with human plasma sourcing. This shift is becoming increasingly necessary; according to the International Plasma and Fractionation Association (IPFA) and European Blood Alliance (EBA) symposium proceedings in August 2025, the European Medicines Agency anticipated plasma shortages to affect 14 European countries in 2024, highlighting the persistent supply challenges for plasma-derived products.

Key Market Players

  • Albumin Therapeutics LLC
  • Biotest AG
  • CSL Limited
  • HiMedia Laboratories
  • Medxbio Pte Ltd.
  • Octapharma AG
  • RayBiotech Inc
  • SeraCare (LGC Clinical Diagnostics, Inc.)
  • Sigma-Aldrich (Merck KGaA)
  • LFB USA , Inc.

Report Scope:

In this report, the Global Albumin Excipient Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Albumin Excipient Market, By Product:

  • Human Serum Albumin
  • Recombinant Albumin

Albumin Excipient Market, By End user:

  • Pharmaceutical and Biotechnology Industry
  • Research Institutes
  • Others

Albumin Excipient Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Albumin Excipient Market.

Available Customizations:

Global Albumin Excipient Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).
Product Code: 20983

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Albumin Excipient Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Human Serum Albumin, Recombinant Albumin)
    • 5.2.2. By End user (Pharmaceutical and Biotechnology Industry, Research Institutes, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Albumin Excipient Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By End user
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Albumin Excipient Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By End user
    • 6.3.2. Canada Albumin Excipient Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By End user
    • 6.3.3. Mexico Albumin Excipient Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By End user

7. Europe Albumin Excipient Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By End user
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Albumin Excipient Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By End user
    • 7.3.2. France Albumin Excipient Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By End user
    • 7.3.3. United Kingdom Albumin Excipient Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By End user
    • 7.3.4. Italy Albumin Excipient Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By End user
    • 7.3.5. Spain Albumin Excipient Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By End user

8. Asia Pacific Albumin Excipient Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By End user
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Albumin Excipient Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By End user
    • 8.3.2. India Albumin Excipient Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By End user
    • 8.3.3. Japan Albumin Excipient Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By End user
    • 8.3.4. South Korea Albumin Excipient Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By End user
    • 8.3.5. Australia Albumin Excipient Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By End user

9. Middle East & Africa Albumin Excipient Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By End user
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Albumin Excipient Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By End user
    • 9.3.2. UAE Albumin Excipient Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By End user
    • 9.3.3. South Africa Albumin Excipient Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By End user

10. South America Albumin Excipient Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By End user
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Albumin Excipient Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By End user
    • 10.3.2. Colombia Albumin Excipient Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By End user
    • 10.3.3. Argentina Albumin Excipient Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By End user

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Albumin Excipient Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Albumin Therapeutics LLC
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Biotest AG
  • 15.3. CSL Limited
  • 15.4. HiMedia Laboratories
  • 15.5. Medxbio Pte Ltd.
  • 15.6. Octapharma AG
  • 15.7. RayBiotech Inc
  • 15.8. SeraCare (LGC Clinical Diagnostics, Inc.)
  • 15.9. Sigma-Aldrich (Merck KGaA)
  • 15.10. LFB USA , Inc.

16. Strategic Recommendations

17. About Us & Disclaimer

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!